ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

ACST Acasti Pharma Inc

2.8501
0.00 (0.00%)
Pre Mercado
Última actualización: 03:00:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Acasti Pharma Inc ACST NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 2.8501 03:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.8501
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
12/2/202407:00EDGAR2Form 8-K - Current report
12/2/202406:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/1/202407:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/1/202406:30EDGAR2Form 8-K - Current report
20/12/202315:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202306:30EDGAR2Form 8-K - Current report
13/11/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202315:30EDGAR2Form 8-K - Current report
16/10/202315:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/10/202315:30EDGAR2Form 8-K - Current report
06/10/202315:30EDGAR2Form S-3 - Registration statement under Securities Act of..
27/9/202318:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202307:10EDGAR2Form 8-K - Current report
05/9/202314:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202316:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
25/8/202315:21EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/8/202315:15EDGAR2Form DEF 14A - Other definitive proxy statements
11/8/202306:31EDGAR2Form 8-K - Current report
11/8/202306:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202316:30EDGAR2Form 8-K - Current report
18/7/202315:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202308:00PRNUSAcasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON..
07/7/202307:30EDGAR2Form 8-K - Current report
07/7/202307:00PRNUSAcasti Pharma Announces 1-for-6 Reverse Stock Split
05/7/202315:00EDGAR2Form 8-K - Current report
05/7/202308:00PRNUSAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase..
23/6/202306:00PRNUSAcasti Pharma Reports Fiscal Year 2023 Operational Results
22/6/202308:00PRNUSAcasti Announces Appointment of New Scientific Advisory..
17/5/202308:00PRNUSAcasti to Participate in the Lytham Partners Spring 2023..
08/5/202306:00PRNUSAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety..

Su Consulta Reciente

Delayed Upgrade Clock